Immunotech Laboraties Appoints New VP of Business Development
15 4월 2013 - 10:25PM
Marketwired
Immunotech Laboratories, Inc. (PINKSHEETS:
IMMB) announces the company has appointed Blaine Nabors as VP of
Business Development.
Immunotech President & Founder Harry Zhabilov today
announced the appointment of Blaine Nabors as Immunotech's VP of
Business Development.
Commencing April 08, 2013, Blaine Nabors reached an agreement
with Immunotech for the position VP of Business Development.
The position includes day-to-day operations along with
assistance for the business marketing strategy and development
along with brand marketing recognition. Additional duties will
include assistance and communication for the FDA Strategy &
Interaction, Regulatory Planning & Execution, Product
Development and its Commercialization.
Active involvement in development of a marketing strategy for
prospective clients along with continued maintenance of public
relations while reviewing, updating and guidance in creating a
marketing plan that will generate relationships with Bio-medical
companies within the same sector.
Mr. Nabors stated, "I'm very pleased to accept this position
offered by Immunotech laboratories. This is such an amazing
creation that can save millions of lives around the world. I'm
honored to be a part of such a revolutionary proprietary treatment
of debilitating infectious diseases. As we move forward to bringing
this recognition to the general public through the FDA process, I
look forward to what lies ahead for Immunotech laboratories and its
further development for all. "
About Immunotech Laboratories Immunotech
Laboratories is a drug development company committed to the
commercialization of its proprietary proteins for the treatment of
debilitating infectious diseases such as HIV and Aids.
www.immunotechlab.com
Safe Harbor Statement: This news release
contains forward-looking statements that involve risks and
uncertainties associated with financial projections, budgets,
milestone timelines, clinical development, regulatory approvals,
and other risks described by Immunotech Laboratories, Inc. from
time to time in its periodic reports filed with the SEC. IPF is not
approved by the US Food and Drug Administration or by any
comparable regulatory agencies elsewhere in the world. While
Immunotech Laboratories believes that the forward-looking
statements and underlying assumptions contained therein are
reasonable, any of the assumptions could be inaccurate, including,
but not limited to, the ability of Immunotech Laboratories to
establish the efficacy of IPF in the treatment of any disease or
health condition, the development of studies and strategies leading
to commercialization of IPF in the United States, the obtaining of
funding required to carry out the development plan, the completion
of studies and tests on time or at all, and the successful outcome
of such studies or tests. Therefore, there can be no assurance that
the forward-looking statements included in this release will prove
to be accurate. In light of the significant uncertainties inherent
in the forward-looking statements included herein, Immunotech
Laboratories or any other person that the objectives and plans of
Immunotech Laboratories will be achieved should not regard the
forward-looking statements as a representation.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Company Contact Email Contact Public Relations The Nabors Group
713-875-9200 E-mail: Email Contact www.facebook.com/Naborsgroup
Immunotech Laborator (CE) (USOTC:IMMB)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Immunotech Laborator (CE) (USOTC:IMMB)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024